KLDO Kaleido Biosciences, Inc.

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMTô). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organís existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

As of 10/18/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/28/2019
Outstanding shares:  42,577,529
Average volume:  143,375
Market cap:   $210,332,993
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    483347100
ISIN:        US4833471000
Valuation   (See tab for details)
PE ratio:   -2.29
PB ratio:   4.11
PS ratio:   170.59
Return on equity:   -179.20%
Net income %:   -7,305.60%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy